Definitive Contract HHSO100201600002C
Ended Awarded Last action
- Contract number
- HHSO100201600002C
- Awardee
-
Basilea Pharmaceutica International Ltd, Allschwil UEI UA43HWRNXFS3
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $108,445,187
Award facts
- Opportunity
-
- BAA13100SOL00013 Solicitation number
- Clinical development of Ceftobiprole Award Notice · Posted Sep 18, 2016
- Contract value 82% obligated
-
- $108,445,186.87 Current, with exercised options
- $132,939,906.87 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Sharing
- Place of performance
- Switzerland
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$2,187,274 | |
| Other Administrative Action | -$119,229 | |
| Funding Only Action | -$1,142,052 | |
| Change Order | $0 | |
| Change Order | $0 | |
| Change Order | $0 | |
| Exercise an Option | $3,157,000 | |
| Change Order | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Change Order | $4,327,818 | |
| Supplemental Agreement for work within scope | $1,500,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $8,000,000 | |
| Exercise an Option | $0 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $10,000,000 | |
| Funding Only Action | $10,000,000 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $54,805,689 | |
| Change Order | $0 | |
| Original award | $20,103,235 |
Show all 21
About this award
The Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Basilea Pharmaceutica International Ltd, Allschwil for advanced development of ceftobiprole, with a ceiling value of $132.9 million and an award date of April 19, 2016.
The contract is structured as cost-sharing, with no set-aside applied. Place of performance is Switzerland. The originating solicitation calls for advanced development of ceftobiprole, a novel antibiotic targeting multidrug-resistant gram-negative bacteria including carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and multidrug-resistant Pseudomonas aeruginosa.
In fiscal year 2024, Basilea invoiced $4.8 million across 3.2 FTEs and 6,694 contractor hours, reflecting a derived government-paid rate of $724.04 per hour. The prime self-performed all reported hours with no subcontractors engaged during that period.
Quick answers
Who was awarded contract HHSO100201600002C?
HHSO100201600002C was awarded to Basilea Pharmaceutica International Ltd, Allschwil by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on April 19, 2016.
How much is contract HHSO100201600002C worth?
The government has obligated $108,445,187 on HHSO100201600002C. Its potential value, with all options, is $132,939,907.
Was contract HHSO100201600002C competed?
The extent of competition for HHSO100201600002C was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award